Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (18)
  • Open Access


    Novel BRCA2-Interacting Protein, LIMD1, Is Essential for the Centrosome Localization of BRCA2 in Esophageal Cancer Cell

    Xiaobin Hou*1, Tinghui Li†1, Zhipeng Ren*, Yang Liu*

    Oncology Research, Vol.24, No.4, pp. 247-253, 2016, DOI:10.3727/096504016X14652175055765

    Abstract Mutation of breast cancer 2, early onset (BRCA2) has been identified as a vital risk factor for esophageal cancer (EC). To date, several proteins have been reported as BRCA2-interacting proteins and are associated with multiple biological processes. This study's aim was to identify a novel interactive protein of BRCA2 and to explore its functional roles in EC. A yeast two-hybrid screening was performed to identify a novel BRCA2-interacting protein. Glutathione-S-transferase (GST) pull-down analysis was performed to find out how the binding domain of BRCA2 interacts with LIM domains containing 1 (LIMD1). The interaction between LIMD1… More >

  • Open Access


    Knockdown of Zinc Transporter ZIP5 by RNA Interference Inhibits Esophageal Cancer Growth In Vivo

    Qian Li, Jing Jin, Jianghui Liu, Liqun Wang, Yutong He

    Oncology Research, Vol.24, No.3, pp. 205-214, 2016, DOI:10.3727/096504016X14648701447896

    Abstract We recently found that SLC39A5 (ZIP5), a zinc transporter, is overexpressed in esophageal cancer. Downregulation of ZIP5 inhibited the proliferation, migration, and invasion of the esophageal cancer cell line KYSE170 in vitro. In this study, we found that downregulation of SLC39A5 (ZIP5) by interference resulted in a significant reduction in esophageal cancer tumor volume and weight in vivo. COX2 (cyclooxygenase 2) expression was decreased and E-cadherin expression was increased in the KYSE170K xenografts, which was caused by the downregulation of ZIP5. However, we did not find that the downregulation of ZIP5 caused a change in More >

  • Open Access


    Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy

    Yue-shen Wang*1, Jing Tian†1, Yong Han, Shu-mei Han, Sheng-bin Shi

    Oncology Research, Vol.24, No.2, pp. 129-135, 2016, DOI:10.3727/096504016X14618564639213

    Abstract We evaluated the efficacy and feasibility of the combination of gemcitabine plus vinorelbine in patients with platinum-based chemotherapy-refractory esophageal cancer. We enrolled 35 patients who received gemcitabine plus vinorelbine as second-line treatment after platinum-based chemotherapy failure between May 2009 and April 2012. Dosage: gemcitabine 1,000 mg/m2 plus vinorelbine 25 mg/m2 ; all drugs were administered on days 1 and 8 of a 21-day cycle, and this was continued until failure or unacceptable toxicity. A total of 125 cycles of treatment were administered, and all patients received at least two cycles of treatment (two to five cycles;… More >

  • Open Access


    Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma

    Hua Tao, Yiqin Zhou, Chengyun Yao, Dayong Gu, Wei Chen, Jincheng Lu

    Oncology Research, Vol.25, No.8, pp. 1357-1362, 2017, DOI:10.3727/096504017X14889842609577

    Abstract The aim of this study was to evaluate the efficacy and toxicity of intensity-modulated radiotherapy concurrent with weekly docetaxel in patients with node-positive esophageal squamous cell carcinoma after radical surgery. Between January 2011 and December 2013, a total of 46 eligible patients were enrolled. All patients received intensity-modulated radiotherapy concurrent with weekly docetaxel (20 mg/m2 ). Patients were treated 5 days per week at 2.0 Gy/day. The total dose of external radiotherapy given was 50 Gy in 25 fractions. The primary endpoints included treatment completion and safety. The secondary endpoint was to assess whether the approach… More >

  • Open Access


    Silencing of Ribosomal Protein L34 (RPL34) Inhibits the Proliferation and Invasion of Esophageal Cancer Cells

    Huijie Fan*1, Jing Li*1, Yongxu Jia*, Jingjing Wu*, Long Yuan, Mingjun Li*, Jiangqi Wei, Benling Xu§

    Oncology Research, Vol.25, No.7, pp. 1061-1068, 2017, DOI:10.3727/096504016X14830466773541

    Abstract Ribosomal protein L34 (RPL34) belongs to the L34E family of ribosomal proteins and contains a zinc finger motif. Aberrant expression of RPL34 has been reported in several human malignancies. However, the precise role and potential underlying mechanisms of RPL34 in human esophageal cancer remain largely unknown. Thus, the objective of this study was to investigate the role of RPL34 in esophageal cancer progression. Our results showed that the expression of RPL34 at both the mRNA and protein levels was frequently upregulated in esophageal cancer cell lines. Knockdown of RPL34 efficiently inhibited esophageal cancer cell proliferation, More >

  • Open Access


    Knockdown of DDX5 Inhibits the Proliferation and Tumorigenesis in Esophageal Cancer

    Zhenchuan Ma*, Jie Feng, Yurui Guo, Ranran Kong*, Yuefeng Ma*, Liangzhang Sun*, Xiaoping Yang*, Bin Zhou*, Shaomin Li*, Wei Zhang*, Jiantao Jiang*, Jin Zhang*, Zhe Qiao*, Yao Cheng*, Danjie Zha*, Shiyuan Liu*

    Oncology Research, Vol.25, No.6, pp. 887-895, 2017, DOI:10.3727/096504016X14817158982636

    Abstract DEAD (Asp-Glu-Ala-Asp) box protein 5 (DDX5), a prototypical member of the DEAD/H-box protein family, has been involved in several human malignancies. However, the expression and biological role of DDX5 in esophageal cancer (EC) remain largely unknown. In this study, we examined the role of DDX5 in regulating EC cell proliferation and tumorigenesis and explored its possible molecular mechanism. We found that DDX5 was overexpressed in human EC cell lines. In addition, knockdown of DDX5 significantly inhibited the proliferation of EC cells in vitro and the growth of EC xenografts in vivo. Knockdown of DDX5 also More >

  • Open Access


    PAQR3 Inhibits the Proliferation and Tumorigenesis in Esophageal Cancer Cells

    Fang Zhou*1, Shunchang Wang†1, Jianjun Wang*

    Oncology Research, Vol.25, No.5, pp. 663-671, 2017, DOI:10.3727/096504016X14761384026719

    Abstract Progestin and adipoQ receptor family member III (PAQR3), a member of the PAQR family, is frequently downregulated in different types of human cancer. However, its expression and functions in esophageal cancer are still unknown. This study aimed to explore the expression of PAQR3 in esophageal cancer cell lines and to investigate the role of PAQR3 in the development of esophageal cancer. Our data showed that PAQR3 is expressed in low amounts in human esophageal cancer cell lines. Overexpression of PAQR3 significantly suppressed the proliferation, migration, and invasion of esophageal cancer cells. In addition, overexpression of More >

  • Open Access


    High TRAF6 Expression Is Associated With Esophageal Carcinoma Recurrence and Prompts Cancer Cell Invasion

    Xinyang Liu*1, Zhichao Wang†1, Guoliang Zhang‡1, Qikun Zhu, Hui Zeng, Tao Wang, Feng Gao, Zhan Qi, Jinwen Zhang§, Rui Wang

    Oncology Research, Vol.25, No.4, pp. 485-493, 2017, DOI:10.3727/096504016X14749340314441

    Abstract Esophageal cancer is one of the most common types of cancer, and it has a poor prognosis. The molecular mechanisms of esophageal cancer progression remain largely unknown. In this study, we aimed to investigate the clinical significance and biological function of tumor necrosis factor receptor-associated factor 6 (TRAF6) in esophageal cancer. Expression of TRAF6 in esophageal cancer was examined, and its correlation with clinicopathological factors and patient prognosis was analyzed. A series of functional and mechanism assays were performed to further investigate the function and underlying mechanisms in esophageal cancer. Expression of TRAF6 was highly… More >

  • Open Access


    Long Noncoding RNA GAS5 Promotes Proliferation, Migration, and Invasion by Regulation of miR-301a in Esophageal Cancer

    Wei Li, Weidong Zhao, Zhaohui Lu, Wen Zhang, Xuan Yang

    Oncology Research, Vol.26, No.8, pp. 1285-1294, 2018, DOI:10.3727/096504018X15166193231711

    Abstract Long noncoding RNA (lncRNA) growth arrest-specific transcript 5 (GAS5) has been revealed to be associated with the progression of various cancers. However, the biological roles of GAS5 in esophageal cancer (EC) remain unclear. We aimed to thoroughly explore the functions of GAS5 in EC. The results showed that GAS5 expression was increased in EC cells (ECA109, TE-1, TE-3, and EC9706) compared to SHEE cells. Knockdown of GAS5 decreased cell viability, migration, and invasion and induced apoptosis in EC9706 cells. Moreover, miR-301a appeared to be directly sponged by GAS5, and miR-301a suppression obviously alleviated the protumor More >

  • Open Access


    [ARTICLE WITHDRAWN] MicroRNA-539 Inhibits the Epithelial‐Mesenchymal Transition of Esophageal Cancer Cells by Twist-Related Protein 1-Mediated Modulation of Melanoma-Associated Antigen A4

    Cao Zhili 1, Zheng Xiang2, Cao Lei1, Liang Naixin1

    Oncology Research, Vol.26, No.4, pp. 529-536, 2018, DOI:10.3727/096504017X14972679378357

    Abstract This article has been withdrawn at the request of the author in December 2020. STATEMENT FOR WITHDRAWAL OF MANUSCRIPT FROM ONCOLOGY RESEARCH Dear Editors, I am Dr. Naixin Liang. For some scientific reasons, my team and I are very sorry to apply to withdraw the manuscript "MicroRNA-539 Inhibits the Epithelial-Mesenchymal Transition of Esophageal Cancer Cells By Twist-Related Protein 1-Mediated Modulation of Melanoma Associated Antigen A4 (MAGEA4)". DOI: 10.3727/096504017 x14972679378357 Because of COVID-19, the lab we worked together was no longer functioning and closed. When reviewing the data of the paper completed in cooperation with the… More >

Displaying 1-10 on page 1 of 18. Per Page